CN110301647A - 地龙蛋白复合低聚肽营养品 - Google Patents
地龙蛋白复合低聚肽营养品 Download PDFInfo
- Publication number
- CN110301647A CN110301647A CN201811438507.XA CN201811438507A CN110301647A CN 110301647 A CN110301647 A CN 110301647A CN 201811438507 A CN201811438507 A CN 201811438507A CN 110301647 A CN110301647 A CN 110301647A
- Authority
- CN
- China
- Prior art keywords
- oligopeptide
- parts
- vitamin
- dragon protein
- nutrient food
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 29
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 21
- 102000004169 proteins and genes Human genes 0.000 title claims abstract description 21
- 235000013305 food Nutrition 0.000 title claims abstract description 18
- 150000001875 compounds Chemical class 0.000 title claims abstract description 16
- 235000015097 nutrients Nutrition 0.000 title claims abstract description 14
- 108010038807 Oligopeptides Proteins 0.000 claims abstract description 58
- 102000015636 Oligopeptides Human genes 0.000 claims abstract description 58
- 239000000843 powder Substances 0.000 claims abstract description 19
- 241000237636 Pheretima Species 0.000 claims abstract description 16
- 210000000988 bone and bone Anatomy 0.000 claims abstract description 14
- 241000251468 Actinopterygii Species 0.000 claims abstract description 13
- 235000009496 Juglans regia Nutrition 0.000 claims abstract description 13
- 241000237502 Ostreidae Species 0.000 claims abstract description 13
- 235000020636 oyster Nutrition 0.000 claims abstract description 13
- 235000020234 walnut Nutrition 0.000 claims abstract description 13
- 241000251511 Holothuroidea Species 0.000 claims abstract description 12
- 239000002994 raw material Substances 0.000 claims abstract description 8
- 239000000463 material Substances 0.000 claims abstract description 7
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims description 32
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 22
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 claims description 16
- 235000019152 folic acid Nutrition 0.000 claims description 16
- 229960000304 folic acid Drugs 0.000 claims description 16
- 239000011724 folic acid Substances 0.000 claims description 16
- 241000758789 Juglans Species 0.000 claims description 12
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims description 11
- 229930003268 Vitamin C Natural products 0.000 claims description 11
- 235000019154 vitamin C Nutrition 0.000 claims description 11
- 239000011718 vitamin C Substances 0.000 claims description 11
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 claims description 10
- 235000013734 beta-carotene Nutrition 0.000 claims description 10
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 claims description 10
- 239000011648 beta-carotene Substances 0.000 claims description 10
- 229960002747 betacarotene Drugs 0.000 claims description 10
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 claims description 10
- -1 folic acid 2mg Chemical compound 0.000 claims description 7
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 6
- 229940000252 folic acid 2 mg Drugs 0.000 claims description 5
- 239000002775 capsule Substances 0.000 claims description 2
- 239000002552 dosage form Substances 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims description 2
- 229940100688 oral solution Drugs 0.000 claims description 2
- RMDJVOZETBHEAR-GHTRHTQZSA-N vitamin d5 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CC[C@H](CC)C(C)C)=C\C=C1\C[C@@H](O)CCC1=C RMDJVOZETBHEAR-GHTRHTQZSA-N 0.000 claims 1
- 208000026106 cerebrovascular disease Diseases 0.000 abstract description 23
- 206010008118 cerebral infarction Diseases 0.000 abstract description 18
- 230000000694 effects Effects 0.000 abstract description 18
- 206010061216 Infarction Diseases 0.000 abstract description 15
- 230000007574 infarction Effects 0.000 abstract description 15
- 208000024891 symptom Diseases 0.000 abstract description 7
- 230000036541 health Effects 0.000 abstract description 5
- 208000019553 vascular disease Diseases 0.000 abstract description 3
- 240000007049 Juglans regia Species 0.000 abstract 1
- 239000000047 product Substances 0.000 description 16
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 10
- MVORZMQFXBLMHM-QWRGUYRKSA-N Gly-His-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)CN)CC1=CN=CN1 MVORZMQFXBLMHM-QWRGUYRKSA-N 0.000 description 9
- 108010038983 glycyl-histidyl-lysine Proteins 0.000 description 9
- 230000002526 effect on cardiovascular system Effects 0.000 description 8
- 229930003316 Vitamin D Natural products 0.000 description 7
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 235000019166 vitamin D Nutrition 0.000 description 7
- 239000011710 vitamin D Substances 0.000 description 7
- 150000003710 vitamin D derivatives Chemical class 0.000 description 7
- 229940046008 vitamin d Drugs 0.000 description 7
- 208000024172 Cardiovascular disease Diseases 0.000 description 6
- 235000013361 beverage Nutrition 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- 230000004089 microcirculation Effects 0.000 description 6
- 239000007787 solid Substances 0.000 description 6
- 230000006870 function Effects 0.000 description 5
- 208000006011 Stroke Diseases 0.000 description 4
- 230000002265 prevention Effects 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- RMDJVOZETBHEAR-LQYWTLTGSA-N vitamin D5 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CC[C@@H](CC)C(C)C)=C\C=C1\C[C@@H](O)CCC1=C RMDJVOZETBHEAR-LQYWTLTGSA-N 0.000 description 4
- 206010008190 Cerebrovascular accident Diseases 0.000 description 3
- 206010020772 Hypertension Diseases 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- 230000008929 regeneration Effects 0.000 description 3
- 238000011069 regeneration method Methods 0.000 description 3
- 239000013589 supplement Substances 0.000 description 3
- 230000002537 thrombolytic effect Effects 0.000 description 3
- 229940088594 vitamin Drugs 0.000 description 3
- 229930003231 vitamin Natural products 0.000 description 3
- 235000013343 vitamin Nutrition 0.000 description 3
- 239000011782 vitamin Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- 208000024827 Alzheimer disease Diseases 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- 208000018152 Cerebral disease Diseases 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 2
- 206010028851 Necrosis Diseases 0.000 description 2
- 208000031845 Pernicious anaemia Diseases 0.000 description 2
- 206010039966 Senile dementia Diseases 0.000 description 2
- 208000007536 Thrombosis Diseases 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 210000005013 brain tissue Anatomy 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 208000029742 colonic neoplasm Diseases 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 2
- 239000010931 gold Substances 0.000 description 2
- 229910052737 gold Inorganic materials 0.000 description 2
- 229910001385 heavy metal Inorganic materials 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 230000017074 necrotic cell death Effects 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 230000035479 physiological effects, processes and functions Effects 0.000 description 2
- 230000035790 physiological processes and functions Effects 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 230000005180 public health Effects 0.000 description 2
- 230000008439 repair process Effects 0.000 description 2
- 208000007442 rickets Diseases 0.000 description 2
- 210000001835 viscera Anatomy 0.000 description 2
- 239000002023 wood Substances 0.000 description 2
- 208000006820 Arthralgia Diseases 0.000 description 1
- 206010004954 Birth trauma Diseases 0.000 description 1
- 208000019743 Cranial nerve injury Diseases 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 108010088842 Fibrinolysin Proteins 0.000 description 1
- 206010016880 Folate deficiency Diseases 0.000 description 1
- 208000010188 Folic Acid Deficiency Diseases 0.000 description 1
- 208000005232 Glossitis Diseases 0.000 description 1
- 206010019468 Hemiplegia Diseases 0.000 description 1
- FFFHZYDWPBMWHY-VKHMYHEASA-N L-homocysteine Chemical compound OC(=O)[C@@H](N)CCS FFFHZYDWPBMWHY-VKHMYHEASA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 206010041349 Somnolence Diseases 0.000 description 1
- 206010047623 Vitamin C deficiency Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 230000003930 cognitive ability Effects 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 210000003792 cranial nerve Anatomy 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 210000003989 endothelium vascular Anatomy 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 229940001501 fibrinolysin Drugs 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 235000001497 healthy food Nutrition 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 108010070324 lumbrokinase Proteins 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 206010027175 memory impairment Diseases 0.000 description 1
- 230000002969 morbid Effects 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 230000001473 noxious effect Effects 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 235000008935 nutritious Nutrition 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 230000008447 perception Effects 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 230000018338 positive regulation of fibrinolysis Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 238000010010 raising Methods 0.000 description 1
- 230000003716 rejuvenation Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- 208000010233 scurvy Diseases 0.000 description 1
- 208000013220 shortness of breath Diseases 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
- A23L33/155—Vitamins A or D
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/18—Peptides; Protein hydrolysates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
本发明涉及保健食品领域，即地龙蛋白复合低聚肽营养品。适合心梗、脑梗及各类血管疾病人群服用。特别适合患陈旧性脑梗、心梗病人的细胞营养和修复。是由以下重量份数的原料组成：地龙蛋白粉15‑35份、海洋鱼低聚肽5‑35份、海参低聚肽5‑15份、牡蛎低聚肽5‑15份、牦牛骨低聚肽10‑15份、核桃低聚肽5‑15份及辅料。对陈旧性心梗、脑梗典型病例31例观察，全部31例主要症状消失，精力充沛，恢复健康，辅助效果显著。
Description
技术领域
本发明涉及保健食品领域，即地龙蛋白复合低聚肽营养品。适合心梗、脑梗及各类血管疾病人群服用。特别适合患陈旧性脑梗、心梗病人的细胞营养和修复。
背景技术
在现有技术中，心梗和脑梗疾病是心脑血管***疾病中的头号杀手，根据***2007年统计数字显示，心脑血管疾病具有“发病率高、致残率高、死亡率高、复发率高,并发症多” 即“四高一多”的特点，目前，我国心脑血管疾病患者已经超过2.7亿人！ 我国每年死于心脑血管疾病近300万人，占我国每年总死亡病因的51%。同时，在40、50岁以上中老年人群中，许多人患病后，由于治疗不利，导致产生不同程度的伤残和各种后遗症。还有许多病人由于不良生活习惯、工作压力过大、健康意识薄弱等原因，已经患有轻度心脑疾病较久而不知，直至体检时，才被发现已呈陈旧性的脑梗或心梗疾病状态。目前，心脑疾病发病率除在中老年人群中呈大面积上升趋势外，更值得注意的是出现年轻化趋势，有的20多岁的青年人也患上心梗或脑梗，甚至抢救无效而死亡……。陈旧性脑梗塞即脑组织缺血中心完全坏死，治疗目的应使梗死区周边组织功能继续得到改善。陈旧性脑梗塞存在较高的复发风险，所以患有陈旧性脑梗塞的患者，治疗及预防同样重要，应减少症状程度，降低高复发率。因此，面对心梗和脑梗等心脑血管疾病，必须引起足够重视，针对发病根源积极采取应对措施，寻求预防、治疗和康复的最佳方案和方法。保健品对心梗、脑梗及各类血管疾病人群有辅助作用，但是目前保健品种类繁多，疗效各异。
发明内容
本发明的目的是针对上述不足而提供一种地龙蛋白复合低聚肽营养品，本产品解决了患陈旧性脑梗、心梗病人的细胞营养和修复问题，辅助效果显著。
本发明的技术解决方案是：地龙蛋白复合低聚肽营养品，其特征在于由以下重量份数的原料组成：地龙蛋白粉15-35份、海洋鱼低聚肽5-35份、海参低聚肽5-15份、牡蛎低聚肽5-15份、牦牛骨低聚肽10-15份、核桃低聚肽5-15份及辅料。辅料是维生素C、维生素D、叶酸、β-胡萝卜素。
优选，地龙蛋白复合低聚肽营养品，其特征在于由以下重量份数的原料组成：地龙蛋白粉35g、海洋鱼低聚肽15g、海参低聚肽15g、牡蛎低聚肽15g、牦牛骨低聚肽15g、核桃低聚肽5g、维生素C1g、维生素D50μg、叶酸2mg、β-胡萝卜素5mg。
剂型为粉剂、颗粒剂，或片剂、胶囊、口服液，但不限于此。
主要原料生产厂家：地龙蛋白肽粉，西安通泽生物科技公司商售产品。洋鱼低聚肽粉，海口原肽生物科技公司商售产品，海参低聚肽粉，浙江绿州生物技术有限公司商售产品。牡蛎低聚肽粉，浙江绿州生物技术有限公司商售产品，牦牛骨低聚肽粉，西安泽邦生物科技有限公司商售产品，核桃低聚肽粉，西安百川生物科技公司商售产品。
本产品是新一代小分子肽类群产品，经合理、优化组合形成的复合胶原蛋白小分子肽群具有对人体更全面的营养补充功效，小分子肽类群是由多种来自不同种蛋白质载体动植物利用生物酶解技术分别制取的低聚肽，经合理配伍形成的寡肽类混合物，克服了单一种类小分子肽营养性欠缺的特点，实现了对细胞的营养作用更大化，激活、抑制、修复和改善细胞的作用更显著。
小分子肽类群具有寡肽种类众多、组成肽的氨基酸种类和微量元素丰富，更适合人体吸收用等众多特点，其平均分子量一般小于700D，对机体细胞的抑制、激活、修复、改善作用更全面、更迅速。
复合低聚肽固体饮料是由海洋罗非鱼低聚肽粉（属水）、核桃低聚肽粉（属木）、海参低聚肽粉（属火）、牦牛低聚肽粉（属土）、牡蛎低聚肽粉（属金）和Vc 、VD、叶酸、β-胡萝卜素等配伍而成，根据“天人合一”的阴阳五行相生理论，选择属性为水、木、火、土、金的五种低聚肽，对应人体五脏六腑相互濡养之需要，对人体补肽功效更全面、迅速、合理。同时，由于含有Vc、 VD、叶酸、β-胡萝卜素等，促进机体生理作用更强盛。本品不含激素、重金属和农残毒，适合所有人群服用。
地龙蛋白粉含有胶原酶、纤溶酶、蚓激酶、纤溶激活蛋白(FA蛋白)、核酸、微量元素等多种成分，其分子量在5000-10000D，属于短链小分子物质。地龙蛋白主要作用是延长体内血栓形成和溶解体内血栓，改善微循环，促进微血管再生，建立侧枝循环，为病灶区的心脑组织开辟新的血液通路，修复坏死的脑神经细胞，治愈偏瘫，从而达到持续溶栓的效果，对心脑血管病的预防，中风后遗症的康复意义重大。同时又有助于消除与微循环障碍有关的衰老和肿瘤发生，改善全身多种生理机能和健康状况，提高免疫力，减少三高对人体的危害。实验证明：地龙蛋白安全无毒、长期食用不会对人体产生不良作用。2009年，***2009年第18号文批准地龙蛋白作为新资源食品。
地龙蛋白粉，地龙蛋白粉具备极高的生物能量和生物活性，可大幅度提高了对血脑屏障的穿透性和溶栓及促进细胞的再生能力，通过《微循环检测仪》检验：地龙蛋白粉可以明显改善人体微循环状态、加速血液流动速度。
海洋鱼低聚肽、海参低聚肽、牡蛎低聚肽、牦牛骨低聚肽、核桃低聚肽类群是运用世界最先进的低温生物定向酶解技术去除脂肪、嘌呤类物质，制备出小分子量（平均＜700D）的低聚肽粉，具有溶解度100%、吸收率100%、生物利用度100% ，无激素、无农残度和有害重金属，安全可靠、无任何毒副作用，是新型的营养健康食品的配料。
维生素C是人体需要量最大的一种维生素维生素。
维生素C具有一系列的生理功能，在历史上曾有万能维生素”之誉，有增强人体免疫功能、预防和治疗缺铁性贫血、恶性贫血、坏血病作用，能促进胶原的形成和类固醇的代谢，有利于维持骨骼和牙齿的正常功能、维持细胞膜的完整性，对某些有毒物质具有解毒作用，还具有抗衰老作用和防癌抗癌作用。
叶酸是生命的守护神。
中老年人也是补充叶酸的重点人群。
① 降低脑卒中风险
数据显示：我国居民叶酸缺乏比例高达 20%~60%。人体缺少叶酸的摄入，容易导致血液中的同型半胱氨酸含量升高，这种物质的升高将直接导致脑中风发生的概率直线上升。
叶酸可改善血管内皮功能，预防冠心病等慢性心血管疾病。由中美医学家联合完成的研究证实，补充叶酸可有效降低脑卒中的风险。
② 预防老年痴呆
对于中老年人来说，充足的叶酸不仅能减少体内有害物质对脑血管的损伤，还有助于减少脑神经损伤造成的认知能力下降以及老年痴呆。
③叶酸助眠、提高记忆力
一旦缺乏叶酸，人体的抵抗力将减弱，会表现出精神萎靡、疲乏无力、失眠健忘、食欲减退，有些人还有舌炎、腹泻、恶性贫血，小儿和老年人常出现嗜睡或精神错乱。
通常我们每天从食物中获取的叶酸约 300 微克，要起到预防作用，最好额外补充200 微克。可怕的是，缺少叶酸的人不会有特别明显的症状，但是他们若同时伴有高血压，那么中风的风险将提高 12 倍！叶酸对人体是普遍有益的，即便没有高血压，充分摄入叶酸，也可以极大减少脑中风的发生概率。
维生素D的作用不可低估。
近几年来越来越多的证据表明，缺乏维生素D可能对身体极其有害。据认为，维生素D除了用于组成和维持骨骼的强壮，防治儿童的佝偻病和成人的软骨症，关节痛等外，对降低结肠癌、乳腺癌和***癌的机率，对免疫***也有增强作用。心美国科学家一项为期40年的研究发现，每天服用一剂维生素D能把罹患乳腺癌、结肠癌和卵巢癌的风险降低一半。心脏病、肺病、癌症、糖尿病、高血压、精神***症和多发性硬化等疾病形成都与缺乏维生素D密切相关，维生素D的作用不可低估。
规格：3.5g/袋×15袋/盒、1000g/袋（固体饮料）。
用法用量：每日早晚各一次，每次1袋，每袋3-5g，用150-200ml温水溶解饮服，可常年服用。
制备方法：按配方量将地龙蛋白肽粉与海洋鱼低聚肽粉、海参低聚肽、牡蛎低聚肽、牦牛骨低聚肽、核桃低聚肽、维生素C、维生素D、叶酸、β-胡萝卜素置入混合机充分混合均匀后，计量分装即可。
本发明的优点是：1、地龙蛋白粉具备极高的生物能量和生物活性，大幅度提高了对血脑屏障的穿透性和溶栓及促进细胞的再生能力，通过《微循环检测仪》检验：地龙蛋白粉可以明显改善人体微循环状态、加速血液流动速度。配伍海洋鱼低聚肽、海参低聚肽、牡蛎低聚肽、牦牛骨低聚肽、核桃低聚肽和维生素C、维生素D、叶酸、β-胡萝卜素等，尤其对陈旧性心梗、脑梗及各类血管疾病具有很好逆转、康复和预防效果。2、为患心脑血管疾病人群提供的营养调理专项产品，具有靶向性强、效果确切，相对经济适用等特点。3、吉林通化康源医药研究所利用本品（固体饮料）对陈旧性心梗、脑梗典型病例31例观察，全部31例主要症状消失，精力充沛，恢复健康，辅助效果显著。
下面将结合实施例对本发明的实施方式作进一步详细描述。
具体实施方式
实施例1
地龙蛋白复合低聚肽营养品，其特征在于由以下重量份数的原料制成：地龙蛋白粉35g、海洋鱼低聚肽15g、海参低聚肽15g、牡蛎低聚肽15g、牦牛骨低聚肽15g、核桃低聚肽5g、维生素C1g、维生素D50μg、叶酸2mg、β-胡萝卜素5mg。
实施例2
地龙蛋白复合低聚肽营养品，其特征在于由以下重量份数的原料制成：地龙蛋白粉25g、海洋鱼低聚肽25g、海参低聚肽15g、牡蛎低聚肽15g、牦牛骨低聚肽15g、核桃低聚肽5g、维生素C1g、维生素D50μg、叶酸2mg、β-胡萝卜素5mg。
实施例3
地龙蛋白复合低聚肽营养品，其特征在于由以下重量份数的原料制成：地龙蛋白粉15g、海洋鱼低聚肽35g、海参低聚肽15g、牡蛎低聚肽15g、牦牛骨低聚肽15g、核桃低聚肽5g、维生素C1g、维生素D50μg、叶酸2mg、β-胡萝卜素5mg。
实验例：
吉林通化康源医药研究所利用本品（固体饮料）对陈旧性心梗、脑梗典型病例31例观察，全部31例主要症状消失，精力充沛，恢复健康，效果显著。具体病例提供如下：
（1）曲女士、女、70岁、陈旧性脑梗、头昏、头晕、肢体无力，服用本品（固体饮料）1年，主要症状消失，精力充沛，步履矫健。
（2）张先生、男、65岁、陈旧性心梗、胸闷气短，浑身无力。服用地龙蛋白复合低聚肽营养品（固体饮料）10个月，主要症状消失，恢复健康，部分头发出现由白变黑的明显生理变化。
Claims (4)
1.地龙蛋白复合低聚肽营养品，其特征在于由以下重量份数的原料组成：地龙蛋白粉15-35份、海洋鱼低聚肽5-35份、海参低聚肽5-15份、牡蛎低聚肽5-15份、牦牛骨低聚肽10-15份、核桃低聚肽5-15份及辅料。
2.按照权利要求1所述的地龙蛋白复合低聚肽营养品，其特征在于辅料是维生素C、维生素D、叶酸、β-胡萝卜素。
3.按照权利要求1或2所述的地龙蛋白复合低聚肽营养品，其特征在于由以下重量份数的原料组成：地龙蛋白粉35g、海洋鱼低聚肽15g、海参低聚肽15g、牡蛎低聚肽15g、牦牛骨低聚肽15g、核桃低聚肽5g、维生素C1g、维生素D50μg、叶酸2mg、β-胡萝卜素5mg。
4.按照权利要求3所述的地龙蛋白复合低聚肽营养品，其特征在于剂型为粉剂、颗粒剂或片剂、胶囊或口服液。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811438507.XA CN110301647A (zh) | 2018-11-29 | 2018-11-29 | 地龙蛋白复合低聚肽营养品 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811438507.XA CN110301647A (zh) | 2018-11-29 | 2018-11-29 | 地龙蛋白复合低聚肽营养品 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN110301647A true CN110301647A (zh) | 2019-10-08 |
Family
ID=68074188
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201811438507.XA Pending CN110301647A (zh) | 2018-11-29 | 2018-11-29 | 地龙蛋白复合低聚肽营养品 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN110301647A (zh) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110652010A (zh) * | 2019-11-01 | 2020-01-07 | 辽宁太爱肽生物工程技术有限公司 | 一种供肠胃不佳人群食用的含肽组合物及应用 |
| CN114916677A (zh) * | 2022-04-18 | 2022-08-19 | 沈阳药大生物科技有限公司 | 一种改善细胞健康状况的低聚肽组合物 |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101418037A (zh) * | 2008-11-14 | 2009-04-29 | 华子昂 | 一种牦牛骨肽及其制备方法 |
| CN102077940B (zh) * | 2010-09-20 | 2013-04-24 | 王强 | 一种冠心病患者专用的海洋特膳食品 |
| CN104208654A (zh) * | 2014-09-05 | 2014-12-17 | 洛阳华以生物工程有限公司 | 一种以地龙蛋白提取物为主的保健配方 |
| CN105476030A (zh) * | 2015-12-15 | 2016-04-13 | 北京天肽生物科技有限公司 | 一种多功能复合低聚肽营养粉 |
-
2018
- 2018-11-29 CN CN201811438507.XA patent/CN110301647A/zh active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101418037A (zh) * | 2008-11-14 | 2009-04-29 | 华子昂 | 一种牦牛骨肽及其制备方法 |
| CN102077940B (zh) * | 2010-09-20 | 2013-04-24 | 王强 | 一种冠心病患者专用的海洋特膳食品 |
| CN104208654A (zh) * | 2014-09-05 | 2014-12-17 | 洛阳华以生物工程有限公司 | 一种以地龙蛋白提取物为主的保健配方 |
| CN105476030A (zh) * | 2015-12-15 | 2016-04-13 | 北京天肽生物科技有限公司 | 一种多功能复合低聚肽营养粉 |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110652010A (zh) * | 2019-11-01 | 2020-01-07 | 辽宁太爱肽生物工程技术有限公司 | 一种供肠胃不佳人群食用的含肽组合物及应用 |
| CN114916677A (zh) * | 2022-04-18 | 2022-08-19 | 沈阳药大生物科技有限公司 | 一种改善细胞健康状况的低聚肽组合物 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101695382A (zh) | 兼具改善骨骼及关节功能的补钙制剂 | |
| CN102178934B (zh) | 一种用于增加骨密度、防治骨关节病及增强免疫力的制剂 | |
| CN101711786B (zh) | 一种用于缓解骨关节病、增强免疫力的制剂 | |
| CN109316517A (zh) | 一种鲜人参膏的制备方法及应用 | |
| CN102726732A (zh) | 一种防治心血管疾病食品的营养补充剂及其应用 | |
| CN102048225B (zh) | 一种具有改善生长发育功能的红枣保健饮料 | |
| CN105768108A (zh) | 一种适用于肿瘤患者服用的特膳食品 | |
| CN103431392A (zh) | 一种供糖尿病患者食用的复合海洋特膳食品 | |
| CN110301647A (zh) | 地龙蛋白复合低聚肽营养品 | |
| CN103599137A (zh) | 一种多种微量营养元素保健品 | |
| RU2309751C1 (ru) | Способ лечения нарушений минерального обмена при артрите, или остеохондрозе, или рахите, или артрозе, или остеопорозе | |
| CN102972672A (zh) | 一种用于补充营养的药物组合泡腾颗粒及其制备方法 | |
| CN101081281A (zh) | 用于提高人体免疫力及抗疲劳的抵抗力胶囊及其制备方法 | |
| CN107788526A (zh) | 一种保护骨关节的营养品 | |
| KR20080090808A (ko) | 피부미용을 위한 건강보조식품의 조성물 | |
| CN103005251A (zh) | 破壁三合一型蜂王浆制品 | |
| CN108815505A (zh) | 提高中老年人骨密度和骨关节功能避免腰腿抽筋的组合物 | |
| CN107969596A (zh) | 一种海参冻干粉固体饮料 | |
| US20180169071A1 (en) | Nutritional supplement composition | |
| CN108371709A (zh) | 黑枸杞肿瘤康复基因酶 | |
| KR102480311B1 (ko) | 체질 맞춤형의 학습 능력 증진용 건강 기능성 식품 조성물 제조방법 | |
| CN107772455A (zh) | 一种含有肉苁蓉的补肾助阳的组合物及即食冲调粉 | |
| CN103933146A (zh) | 一种可调节人体免疫力的花粉制品 | |
| CN105287943A (zh) | 复方火麻仁胶囊及其制备方法和应用 | |
| CN101007127A (zh) | 一种复方雄蚕蛾男性保健药酒和制法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20191008 |
|
| RJ01 | Rejection of invention patent application after publication |